Zacks: Brokerages Anticipate KITOV PHARMA LT/S (KTOV) Will Announce Earnings of -$0.01 Per Share

Brokerages predict that KITOV PHARMA LT/S (NASDAQ:KTOV) will announce earnings of ($0.01) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for KITOV PHARMA LT/S’s earnings. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that KITOV PHARMA LT/S will report full-year earnings of ($0.03) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.02) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for KITOV PHARMA LT/S.

KTOV has been the subject of several research analyst reports. Zacks Investment Research raised KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research note on Friday, June 15th. HC Wainwright reissued a “buy” rating and set a $12.50 price target on shares of KITOV PHARMA LT/S in a research report on Tuesday, June 19th.

NASDAQ KTOV traded up $0.02 during mid-day trading on Friday, hitting $1.62. The stock had a trading volume of 54,617 shares, compared to its average volume of 268,601. KITOV PHARMA LT/S has a 52-week low of $1.55 and a 52-week high of $3.81. The company has a market capitalization of $27.26 million, a P/E ratio of -1.25 and a beta of 2.43.

KITOV PHARMA LT/S Company Profile

Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Recommended Story: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with's FREE daily email newsletter.

Leave a Reply